Sichuan Kelun Pharmaceutical Co., Ltd.
科伦药业
002422
Shenzhen Stock Exchange
Company Profile
(1) Strategic Decision-making Ability and Execution Ability In the development process, the company's strategic decisions, formed by its keen insight into the development environment and its predictive ability of the industry development trends, have enabled the company to seize a series of historical opportunities: Firstly, the entrepreneurial opportunity in 1996 with low cost and low industry threshold; Secondly, the market opportunity in 2000 when hospital infusion preparation rooms were closed; Thirdly, the opportunity in 2003 when the upgrade and replacement of infusion products were forced by SARS; Fourthly, the opportunity in 2008 when the global financial crisis led to a major reshuffle in the antibiotic industry; Fifthly, the opportunity in 2013 when sterile drug production enterprises were required to be compulsorily certified through the new version of GMP; Sixthly, the R&D strategic layout of "driving innovation through generic drugs and driving the future through innovation" has led the wave of Chinese innovative drugs going global. At the same time, the company has actively responded to and participated in the centralized drug procurement with volume and the national medical insurance negotiations organized by the state and local governments. The company not only has strategic decision-making ability but also possesses extremely strong team execution ability. The corporate execution culture of "first inquiry responsibility system" and "24-hour feedback system" has taken root in the hearts of employees and is deeply embedded in every business activity. (2) Firm and Clear Development Strategy The company has a clear and firm corporate strategy at every stage of its development. In the initial stage of entrepreneurship in 1996, the company's development strategy was "cost leadership, market-driven"; On the occasion of the company's tenth anniversary, it put forward the development strategy of "two transformations" in a forward-looking manner, that is, "transforming from entrepreneurial operation to large-scale operation and from the mission of wealth to organizational inheritance"; After being listed in 2010, the company formulated the development strategy of "three engines driving". Over the past 14 years, the company has continuously strived to achieve the strategic goal of "three engines driving, innovation for growth". (3) Possessing Capital Conditions and Resource Strength Matching the Development Strategy In order to achieve the development strategy of "three engines driving, innovation for growth", the company has corresponding capital conditions and resource strength. Through continuous industrial upgrading and adjustment of product variety structure, the company has established the overall advantage of the injection product cluster including large-volume infusions, maintained its leading position in the infusion field, and continuously provided sufficient cash flow for innovative growth. In 2022, Chuanning Biotech was successfully listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, and in 2023, Kelun-BoTai Biotech was successfully listed on the Main Board of the Stock Exchange of Hong Kong, marking the deep integration of industry and capital and a significant improvement in the overall capital strength. Relying on its strong capital conditions and resource strength, the company conducts research and development of high-tech drugs such as innovative small molecule drugs, biotech drugs, new drug delivery systems and excellent generic drugs through diversified technological innovation, expands international cooperation resources, and is accumulating the ultimate driving force for the long-term development of the enterprise. (4) The Combination of Talent and Technology, Highlighting the Innovative Advantage Innovation is the soul of enterprise competition. At the end of 2012, the company fully launched its innovative transformation, attracting thousands of doctors and masters to join. It has built a scientific research team with high scientific level, strong fighting will, reasonable talent structure and international standards, including leading talents with rich international research experience, as well as a R&D and innovation 承接 team in the production base mainly composed of doctors and masters. The company makes full use of excellent domestic and foreign research talents and other competitive resources, and has established a multi-technology category and full-function platform R&D system focusing on innovative research, with Kelun-BoTai Biotech, KLUS in the United States, Kelun Pharmaceutical Research Institute and its Suzhou Branch, and Shanghai Ruikang Biotech as the main bodies. It has formed a new R&D model that is mainly driven by domestic forward R&D and supplemented by foreign technology feedback, and is fully in line with international standards; Relying on innovative platforms such as the national-level enterprise technology center, post-doctoral research workstation, and the National Engineering Technology Research Center for Large-Volume Injection Preparations, the company conducts high-level cooperation across specialties, regions and ownership forms with relevant knowledge alliance institutions. Innovative ability has become the core competitiveness of Kelun. (5) Strong Team Inheritance and Innovation Ability The company's subsidiaries (branches) are located in 16 provinces (municipalities directly under the central government, autonomous regions) across the country, the Hong Kong Special Administrative Region, as well as countries such as the United States and Kazakhstan. In the initial stage of entrepreneurship, the company formulated the "long bench plan" for talent cultivation, that is, from team leaders at the grassroots level to the senior management team of the enterprise, each level must cultivate their own successors. This cultivation mechanism has provided efficient and useful human resources guarantee for the company's rapid expansion. At present, the company is not only rich in talents but also has carried out orderly generational handovers. High-quality management division of labor and cultural inheritance are important signs of a company's good governance. Currently, the company's organizational culture is transforming from power distribution to value flow. Hundreds of excellent professional managers are leading about 20,000 employees to turn Kelun's ideals into reality. The ability of the company's elite team to continuously replicate has contributed to the company's current stable and vigorous development trend, and is also a powerful driving force for its continuous development in the future.
Full description
Kelun was founded in 1996. Currently, it has formed an operating platform with a "pin" - shaped structure composed of Kelun Pharmaceutical (002422.SZ), Chuanning Biotech (301301.SZ), and Kelun-BoTai (06990.HK), with a total market value of over 100 billion yuan. In 2017, Kelun ranked 155th among the top 500 Chinese manufacturing enterprises. In 2018, relying on its global advantage in large-volume injections, Kelun was awarded the title of "Demonstration Enterprise of Single Champion in Manufacturing". In 2023, Kelun ranked among the top three in China's pharmaceutical manufacturing industry. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010. Immediately after that, it launched a 10-billion-yuan industrial investment plan and began to implement the development strategy of "Three Engines Driving, Innovation for Growth". The first engine is to maintain Kelun's leading position in the infusion field through continuous industrial upgrading and adjustment of product variety structure; the second engine is to build a competitive advantage in antibiotics from intermediates, APIs to preparations through the innovative development and utilization of high-quality natural resources; the third engine is to accumulate the ultimate driving force for the long-term development of the enterprise through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved a comprehensive industrial upgrade, possessing the profitability characterized by high-end manufacturing and new materials, and occupying the strategic high ground of technological innovation and quality benchmarking. Kelun has established a closed-loop responsibility system covering the research and development, production, logistics and transportation, and terminal use of drugs to ensure product quality and safety. Its leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The independently developed Keli Bag® by Kelun is the first of its kind at home and abroad, and has won the National Science and Technology Progress Award, leading the development direction of safe infusion; the iterative products with unique integrated technical advantages - the ready-to-prepare high-end infusions (parenteral nutrition multi-chamber bags and antibiotic solid-liquid double-chamber bags) have taken the lead in breaking the foreign monopoly and have become the preferred medical drugs in case of epidemic situations, wars and natural disasters, establishing the brand image of a national enterprise in China's high-end infusion market. In the field of antibiotics, the company advanced westward and established Yili Chuanning Biotechnology Co., Ltd. Through the innovative development and utilization of high-quality natural resources in Xinjiang, it combines modern manufacturing and modern agriculture across industries, achieves key breakthroughs in key technologies and core links of biological fermentation, and completely solves the problem of "treatment of three wastes". It has grown into a green environmental protection benchmark in China and a leading enterprise with global influence in the field of antibiotics. In December 2022, Chuanning Biotech was successfully listed on the Growth Enterprise Market of the Shenzhen Stock Exchange. Combining its own industrial advantages, it is fully implementing the development strategy of "dual-wheel drive of biological fermentation and synthetic biology", aiming to become a professional manufacturer of biological products with global competitiveness and influence. Up to now, Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patent authorizations. It has successively launched the research and development of more than 500 major drugs in multiple disease areas such as oncology, bacterial infections, and parenteral nutrition. Since 2017, more than 20 products have been approved for listing each year, making it a leading enterprise in generic drugs in China. With a selection rate of nearly 90%, it has become a leading supplier in the national centralized drug procurement. At the same time, more than a dozen innovative drug projects for the treatment of major diseases such as tumors, autoimmune diseases, inflammation, and metabolism are in the clinical stage. Many clinical trials are global multi-center studies, and multiple projects cooperate with European and American partners to lay out global clinical research, which are carried out simultaneously in multiple countries including China, Europe and the United States, so as to achieve a synergistic effect of the pipeline and technology platform and maximize the global value of the pipeline. Kelun-BoTai has successfully established an internationally renowned ADC R&D platform. In 2022, it successfully reached three major licensing cooperation agreements with the multinational giant Merck & Co., with a total contract value of over 10 billion US dollars. This not only ranks first in the history of international licensing transactions in China's pharmaceutical industry, but also tops the list of the top 10 licensing transaction cooperations in the global pharmaceutical industry in 2022, laying a solid foundation for Kelun's position in the first echelon of innovative drug research and development in China. In July 2023, Kelun-BoTai was successfully listed on the Stock Exchange of Hong Kong, marking the beginning of a new journey for Kelun's innovative R&D and global layout. With the successive approval and launch of the first Chinese original and internationally high-quality TROP2 ADC Jitailai® and the world's first PD-L1 monoclonal antibody for nasopharyngeal carcinoma Ketailai®, Kelun has opened up a new treatment path for cancer patients and brought new hope. Adhering to the corporate tenet of "Seeking Truth in Science and Goodness in Ethics", Kelun has donated more than 300 million yuan to social welfare undertakings, the Guangcai Program and charitable causes over the years, demonstrating Kelun's view on the quality of wealth and social justice, and showing the good image of an excellent private enterprise developing healthily under the market economy conditions.